Moleculin Biotech announced the publication of a peer-reviewed analysis in "Frontiers in Cardiovascular Medicine" detailing favorable cardiac safety findings for its lead drug candidate, Annamycin. The analysis, which pooled data from five clinical trials, found no evidence of treatment-related cardiotoxicity, a common side effect that limits the use of conventional drugs in its class (anthracyclines).
Key Details
- Publication Scope: The analysis covered 90 patients treated with Annamycin across five clinical trials for acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS).
- Primary Finding: The study found no clinical or subclinical evidence of cardiotoxicity, even at cumulative doses (median 660 mg/m²) that exceed traditional lifetime limits for other anthracyclines.
- Cardiac Function: Mean Left Ventricular Ejection Fraction (LVEF), a key measure of heart health, remained stable with no statistically significant change (60.6% baseline vs. 60.0% post-treatment).
- Independent Validation: The data was independently evaluated by a cardio-oncology laboratory at the Cleveland Clinic, supporting the continued development of Annamycin as a potentially safer anthracycline.